Evaxion Biotech A/S — FY2023 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone Q4 filing. Financial statements are audited and prepared under IFRS in U.S. dollars. Evaxion is a Danish clinical-stage TechBio company with no approved products and limited revenue.
Business context
Evaxion uses its AI-Immunology platform to discover vaccine targets and develop candidates for cancer and infectious diseases. Its strategy was refocused in 2023 toward earlier, broader partnerships—alongside developing selected candidates toward proof of concept—to reduce the company’s clinical-development spending and monetize its platform, pipeline, and responder models.
EVX-01 was in a Phase 2 melanoma trial with pembrolizumab; EVX-02 completed a Phase 1/2a study; EVX-03 was described as clinically ready but dependent on a development partner. Infectious-disease candidates remained preclinical or in collaborative discovery.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0.073 million | Nil |
| Research and development expense | $11.916 million | $17.056 million |
| General and administrative expense | $10.354 million | $8.208 million |
| Operating loss | $22.197 million | $25.264 million |
| Net loss | $22.125 million | $23.169 million |
| Cash used in operating activities | $17.691 million | $25.774 million |
| Cash and cash equivalents at year-end | $5.583 million | $13.184 million |
| Total assets | $12.889 million | $22.025 million |
| Total liabilities | $17.618 million | $13.722 million |
| Total equity (deficit) | $(4.729) million | $8.303 million |
Revenue was a milestone-related service payment under the MSD collaboration; the filing reports no material product sales. Gross margin is not separately presented. At year-end, borrowings were $8.648 million, including the EIB loan and a lessor loan. The balance sheet also included a $2.714 million derivative liability and a $0.190 million warrant liability. The company reported no material off-balance-sheet arrangements.
The auditor included a going-concern explanatory paragraph. Management said the company needs additional financing and disclosed substantial doubt about its ability to continue as a going concern. The filing estimated year-end cash would fund operations into February 2025; the February 2024 offering was expected to extend runway, potentially into April 2025 if prefunded warrants are exercised.
Changes versus prior year
- Revenue increased from nil to $73,000, principally from an MSD development milestone.
- R&D expense fell by $5.140 million, mainly due to lower clinical and external costs and reduced headcount.
- G&A expense rose by $2.146 million, primarily from legal, professional, financing, and personnel costs.
- Net loss narrowed by $1.044 million, while cash fell by $7.601 million and equity moved from positive $8.303 million to a $4.729 million deficit.
- Headcount fell to 49 from 63 at year-end 2022. The company also reprioritized programs and reduced clinical-development activity.
Outlook, risks, and unusual items
- Outlook: Management’s 2024 ambition was to generate business-development revenue equal to estimated 2024 cash burn of $14 million, excluding financing activities. This is an aspiration, not assured guidance. Management expects continuing losses and requires additional capital.
- Financing and dilution: The December 2023 private placement raised approximately $5.3 million gross and included warrants for up to 9.7 million shares. A February 2024 public offering was reported to produce approximately $12.6 million net in one disclosure and $12.7 million in another; prefunded warrants and accompanying warrants could provide additional proceeds. The ATM raised approximately $6.3–$6.4 million in 2023, with differing figures in the filing. Lincoln Park and GGH facilities were not operational or available for use as of year-end.
- Clinical and partnership risk: All candidates remain investigational. Clinical results are early and based on small cohorts; later trials may not reproduce them. Progress and potential revenue depend heavily on securing and retaining partners, including for EVX-03.
- Clinical timing: EVX-01 Phase 2 initial data from five patients were described as encouraging; 16 patients had enrolled by November 2023. The company expected a one-year readout in Q3 2024 and full study results in 2025. EVX-02 results included 10 patients completing the full dosing schedule; all were relapse-free at their last assessment, and nine were relapse-free at the 12-month visit. These are limited, early-stage observations, not proof of efficacy.
- Controls: Management found a material weakness in internal control over financial reporting involving review-control execution and documentation, including information produced by the entity. Disclosure controls were also deemed ineffective as of December 31, 2023. Remediation and training were planned; success is not assured.
- Contingency: SSI’s patent-ownership litigation concerning an EVX-01-related application was paused while negotiations proceeded. The parties reached terms in December 2023 under which Evaxion would retain commercial rights and pay no compensation, but formal agreements remained unsigned at the report date.
- Other risks: The company faces manufacturing and supply-chain dependence, regulatory and clinical uncertainty, IP disputes, possible future equity dilution, currency exposure, and cybersecurity and geopolitical risks. It pays no dividend and does not expect to do so in the foreseeable future.
Most important facts for investors to verify
- Current cash runway and financing availability, including exercise and escrow terms for February 2024 prefunded warrants and the status of the Lincoln Park and GGH facilities.
- The final net proceeds and share dilution from the February 2024 offering, and the ATM proceeds figure, given inconsistent amounts in the filing.
- Progress on the 2024 business-development revenue ambition and whether executed partnerships include material upfront, milestone, or royalty economics.
- EVX-01 enrollment, safety, and efficacy as larger Phase 2 datasets mature; independently assess the small early cohorts and historical comparisons cited by management.
- Whether the SSI settlement was formally executed and the litigation closed, and whether it affects EVX-01 intellectual-property rights.
- Remediation of the material weakness and improved financial-control documentation in subsequent filings.
- Debt repayment and cash obligations, including the EIB loan, lease commitments, and cash-settled EIB warrants.